EHElizabeth Hammond

Elizabeth Hammond

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Hammond has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treating Lower Phantom Limb Pain in the Postoperative Acute Care Setting Using Virtual Reality: Protocol for a 4-Phase Development and Feasibility Trial

    by Renée El-Gabalawy, Megan Crooks, Michael Sean Dyck Smith, Elizabeth Hammond, Patrick Gross, Marinya Roznik, David Perrin, Kristin Reynolds, Gabrielle Logan, Lily Pankratz, et al.

    Background: Phantom limb pain (PLP) affects most people living with lower limb amputations (LLAs). Nonpharmacological interventions, such as graded motor imagery (GMI), have demonstrated promise as PLP treatments. However, GMI access is limited by low patient buy-in and long public outpatient wait times. Considering PLP has been shown to be more prevalent and severe immediately following LLA, there is an urgent need to bypass barriers to allow for prompt access to PLP interventions. In response to this need, the multidisciplinary research team in this study developed a virtual reality (VR) program that administers GMI treatment. This novel intervention may be completed independently and promptly within the postoperative acute care setting. Before conducting a randomized controlled trial, the VR-GMI program must be developed and refined through a rigorous and multistage feasibility assessment. Objective: This protocol aims to outline the development and feasibility of the VR-GMI prototype for treating people with LLAs in the postoperative acute care setting (ie, inpatient and home settings) through an iterative, patient-centered, and descriptive approach. Methods: Four phases of prototype development and assessment were conducted. In phase 1 (completed), the VR-GMI prototype was developed in collaboration with engineers at the National Research Council and in consultation with patient partners. In phase 2 (completed), people with lived experience with amputations were recruited from local physiotherapy and prosthetic clinics to trial the VR-GMI program and provide feedback through semistructured interviews and self-report measures. Phase 3 (completed) consisted of a descriptive case series of individuals who trialed the VR-GMI prototype immediately following their LLAs in the hospital. Results from phase 3 informed the development of a primary quantitative feasibility study. Phase 4 (underway) aims to evaluate the acceptability and pilot outcomes of the VR-GMI program in hospital and home settings as well as improve study procedures for a future randomized controlled trial (phase 4A). Iterative developments were made to the VR-GMI program between each phase to improve prototype fidelity. These iterative developments will also be reviewed in a series of focus groups to finalize the VR-GMI prototype (phase 4B). Results: Recruitment for phases 1 and 2 was completed in September 2023. Phase 3 was completed in July 2024, and phase 4A is currently underway with 15 participants recruited as of March 2025. Conclusions: The intervention developed is the first VR PLP treatment implementing GMI and prioritizing an in-depth, patient-centered approach before assessing its efficacy. Doing so will improve the likelihood of successful clinical implementation. Moreover, very few PLP interventions have been assessed in the acute postoperative period when they may prevent PLP before its onset. Trial Registration: ClinicalTrials.gov NCT06638918; https://clinicaltrials.gov/study/NCT06638918 International Registered Report Identifier (IRRID): DERR1-10.2196/68008


  • Open Access

    Treating Lower Phantom Limb Pain in the Postoperative Acute Care Setting Using Virtual Reality: Protocol for a 4-Phase Development and Feasibility Trial (Preprint)

    by Renée El-Gabalawy, Megan Crooks, Michael Sean Dyck Smith, Elizabeth Hammond, Patrick Gross, Marinya Roznik, David Perrin, Kristin Reynolds, Gabrielle Logan, Lily Pankratz, et al.

    BACKGROUND Phantom limb pain (PLP) affects most people living with lower limb amputations (LLAs). Nonpharmacological interventions, such as graded motor imagery (GMI), have demonstrated promise as PLP treatments. However, GMI access is limited by low patient buy-in and long public outpatient wait times. Considering PLP has been shown to be more prevalent and severe immediately following LLA, there is an urgent need to bypass barriers to allow for prompt access to PLP interventions. In response to this need, the multidisciplinary research team in this study developed a virtual reality (VR) program that administers GMI treatment. This novel intervention may be completed independently and promptly within the postoperative acute care setting. Before conducting a randomized controlled trial, the VR-GMI program must be developed and refined through a rigorous and multistage feasibility assessment. OBJECTIVE This protocol aims to outline the development and feasibility of the VR-GMI prototype for treating people with LLAs in the postoperative acute care setting (ie, inpatient and home settings) through an iterative, patient-centered, and descriptive approach. METHODS Four phases of prototype development and assessment were conducted. In phase 1 (completed), the VR-GMI prototype was developed in collaboration with engineers at the National Research Council and in consultation with patient partners. In phase 2 (completed), people with lived experience with amputations were recruited from local physiotherapy and prosthetic clinics to trial the VR-GMI program and provide feedback through semistructured interviews and self-report measures. Phase 3 (completed) consisted of a descriptive case series of individuals who trialed the VR-GMI prototype immediately following their LLAs in the hospital. Results from phase 3 informed the development of a primary quantitative feasibility study. Phase 4 (underway) aims to evaluate the acceptability and pilot outcomes of the VR-GMI program in hospital and home settings as well as improve study procedures for a future randomized controlled trial (phase 4A). Iterative developments were made to the VR-GMI program between each phase to improve prototype fidelity. These iterative developments will also be reviewed in a series of focus groups to finalize the VR-GMI prototype (phase 4B). RESULTS Recruitment for phases 1 and 2 was completed in September 2023. Phase 3 was completed in July 2024, and phase 4A is currently underway with 15 participants recruited as of March 2025. CONCLUSIONS The intervention developed is the first VR PLP treatment implementing GMI and prioritizing an in-depth, patient-centered approach before assessing its efficacy. Doing so will improve the likelihood of successful clinical implementation. Moreover, very few PLP interventions have been assessed in the acute postoperative period when they may prevent PLP before its onset. CLINICALTRIAL ClinicalTrials.gov NCT06638918; https://clinicaltrials.gov/study/NCT06638918 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/68008

  • Open Access

    “Another Tool in Your Toolkit”: Pediatric Occupational and Physical Therapists’ Perspectives of Initiating Telehealth during the COVID-19 Pandemic

    by Kristy D. M. Wittmeier, Elizabeth Hammond, Kaitlyn Tymko, Kristen Burnham, Tamara Janssen, Arnette J. Pablo, Kelly Russell, Shayna Pierce, Carrie Costello, Jennifer L. P. Protudjer

    Pediatric occupational and physical therapy service delivery via telehealth increased during the COVID-19 pandemic. Real-world experience can guide service improvement. This study explored experien...


  • An Exploratory Randomized Trial of Physical Therapy for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

    by Elizabeth Andersen Hammond, Marshall Pitz, Karen Steinfeld, Pascal Lambert, Barbara Shay

    Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of taxane treatment and cannot currently be prevented or adequately treated. Physical therapy is often used for neural rehabilitation following injury but has not been evaluated in this patient population. Methods. Single-blind, randomized controlled exploratory study compared standard care to a physical therapy home program (4 visits) throughout adjuvant taxane chemotherapy for stage I-III patients with breast cancer (n = 48). Patient questionnaires and quantitative sensory testing evaluated the treatment effect throughout chemotherapy to 6 months post treatment. Nonrandomized subgroup analysis observed effect of general exercise on sensory preservation comparing those reporting moderate exercise throughout chemotherapy to those that did not exercise regularly. Clinical Trial Registration. clinicaltrials.gov (NCT02239601). Results. The treatment group showed strong trends toward less pain (odds ratio [OR] 0.41, 95% confidence interval [CI] 0.17-1.01; P = .053) and pain decreased over time (OR 0.85, 95% CI 0.76-0.94; P = .002). Pain pressure thresholds (P = .034) and grip dynamometry (P < .001) were improved in the treatment group. For the nonrandomized subgroup analysis, participants reporting general exercise had preservation of vibration (Left P = .001, Right P = .001) and normal heat pain thresholds (Left P = .021, Right P = .039) compared with more sedentary participants. Conclusion. Physical therapy home program may improve CIPN pain in the upper extremity for patients with breast cancer, and general exercise throughout chemotherapy treatment was observed to have correlated to preservation of sensory function. Further research is required to confirm the impact of a physical therapy home program on CIPN symptoms.


  • Neuropathic Pain in Taxane-Induced Peripheral Neuropathy: Evidence for Exercise in Treatment

    by Elizabeth Andersen Hammond, Marshall Pitz, Barbara Shay

    One in 2 Canadians is expected to acquire cancer in their lifetime. Many cancers, including breast, ovarian, and lung cancer, are treated using taxane chemotherapy with curative intent. A major adverse effect with the use of taxane chemotherapeutic agents is taxane-induced peripheral neuropathy (TIPN). Both positive (spontaneous pain, heightened sensitivity with light touch, tingling, itching, burning) and negative (loss of touch, loss of hot/cold sensations, and loss of pain) sensory symptoms can be experienced in the hands and feet and worsen with increasing dose and treatment duration. The pathophysiology of TIPN is still unknown but likely involves multiple mechanisms, including microtubule impairment, neuroimmune and inflammatory changes, ion channel remodeling, impaired mitochondrial function, and genetic predisposition. This review highlights current theories on the pathophysiology for TIPN, the cellular responses thought to maintain neuropathic pain, and the growing support for exercise in the treatment and prevention of peripheral neuropathy and neuropathic pain in both animal and human models.


  • Open Access

    Quantitative sensory profiles of upper extremity chemotherapy induced peripheral neuropathy: Are there differences in sensory profiles for neuropathic versus nociceptive pain?

    by Elizabeth Andersen Hammond, Marshall Pitz, Pascal Lambert, Barbara Shay

    Aims: To define the sensory phenotypes of taxane induced peripheral neuropathy (TIPN) in a breast cancer population between neuropathic and non-neuropathic symptoms to identify future targets for mechanism-based pain management. Methods: Participants (n = 48) with stage I-III breast cancer. Self-report questionnaires and Quantitative Sensory Testing were used to assess sensory symptoms. The Self report version of the Leeds Assessment for Neuropathic Symptoms and Signs (S-LANSS) divided the groups into neuropathic and non-neuropathic sensory phenotypes. In total, 5 visits over approximately 8 months assessed each participant from pre-chemotherapy to 6 months post-chemotherapy. Results: 191 nerve assessments, 150 had a S-LANSS 12, which was defined as “neuropathic”. NPRS was analyzed based on percentages of those experiencing 1+ pain (graded 1/10 or higher) versus no pain. The neuropathic group had 82.9% of 1+ pain vs 28.7% in the non-neuropathic group (OR 7.49, 95% CI 2.76–20.3, p = .001). The neuropathic group reported impaired function on the DASH (p = .002). Heat pain threshold resulted in statistical differences for the left, but not right hand in the neuropathic group (p = .05). No other quantitative data on warm/cool or cold, or vibration demonstrated sensory differences between the groups. Conclusions: Few differences in QST measured sensory profiles were found. Heat pain thresholds were normalized possibly suggesting that the neuropathic group retained C-fiber and TRPV1 function. Participants with neuropathic pain demonstrated significant differences with increased pain and decreased function.


  • Population-based analysis of breast cancer treatment by intrinsic sub-type in Manitoba, Canada

    by Elizabeth Hammond, Emma Shu, Karagin Sawchuk, Yvonne Myal, Afshin Raouf, Thomas Klonisch, Sabine Hombach-Klonisch, Etienne Leygue, Sam Kung, Janice Safneck, et al.


  • Objective Evaluation of Fine Motor Manipulation—A New Clinical Tool

    by Elizabeth R. Andersen Hammond, Barbara L. Shay, Tony Szturm